(NASDAQ: ENSC) Ensysce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 221.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.76%.
Ensysce Biosciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ENSC's revenue for 2025 to be $9,973,972, with the lowest ENSC revenue forecast at $3,918,346, and the highest ENSC revenue forecast at $16,029,598. On average, 1 Wall Street analysts forecast ENSC's revenue for 2026 to be $29,684,440, with the lowest ENSC revenue forecast at $29,684,440, and the highest ENSC revenue forecast at $29,684,440.
In 2027, ENSC is forecast to generate $104,251,753 in revenue, with the lowest revenue forecast at $104,251,753 and the highest revenue forecast at $104,251,753.